Envestnet Asset Management Inc Fibrogen Inc Transaction History

Envestnet Asset Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$18.57 - $35.68 $427,277 - $820,961	-23,009 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$31.0 - $55.72 $54,901 - $98,680	1,771 Added 8.34%	23,009 $799,000
Q4 2020 Feb 02, 2021	SELL	$37.09 - $48.97 $271,053 - $357,872	-7,308 Reduced 25.6%	21,238 $788,000
Q3 2020 Oct 09, 2020	BUY	$40.47 - $45.5 $187,942 - $211,302	4,644 Added 19.43%	28,546 $1.17 Million
Q2 2020 Jul 08, 2020	SELL	$32.57 - $42.83 $71,686 - $94,268	-2,201 Reduced 8.43%	23,902 $969,000
Q1 2020 Apr 23, 2020	BUY	$23.3 - $45.96 $121,369 - $239,405	5,209 Added 24.93%	26,103 $907,000
Q4 2019 Feb 11, 2020	SELL	$34.58 - $48.06 $49,795 - $69,206	-1,440 Reduced 6.45%	20,894 $896,000
Q3 2019 Oct 17, 2019	BUY	$36.98 - $48.45 $32,579 - $42,684	881 Added 4.11%	22,334 $826,000
Q2 2019 Aug 02, 2019	BUY	$35.13 - $55.53 $48,865 - $77,242	1,391 Added 6.93%	21,453 $969,000
Q1 2019 May 10, 2019	BUY	$42.83 - $59.91 $659,539 - $922,554	15,399 Added 330.24%	20,062 $1.09 Million
Q4 2018 Feb 13, 2019	BUY	$37.97 - $60.16 $177,054 - $280,526	4,663 New	4,663 $216,000
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $48,418 - $57,835	-860 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$44.9 - $64.95 $11,718 - $16,951	261 Added 43.57%	860 $54,000
Q1 2018 May 09, 2018	BUY	$45.35 - $61.65 $11,609 - $15,782	256 Added 74.64%	599 $27,000
Q4 2017 Feb 20, 2018	SELL	$41.95 - $60.1 $16,738 - $23,979	-399 Reduced 53.77%	343 $17,000
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $24,782 - $39,993	742	742 $40,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.